scholarly journals The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn's disease

Author(s):  
Céline Gregoire ◽  
Chantal Lechanteur ◽  
Alexandra Briquet ◽  
Etienne Baudoux ◽  
Olivier Giet ◽  
...  
2021 ◽  
Vol 12 (1) ◽  
pp. 56-66
Author(s):  
Toumi Ryma ◽  
Arezki Samer ◽  
Imene Soufli ◽  
Hayet Rafa ◽  
Chafia Touil-Boukoffa

Inflammatory Bowel Disease (IBD) is a term used to describe a group of complex disorders of the gastrointestinal (GI) tract. IBDs include two main forms: Crohn’s Disease (CD) and Ulcerative Colitis (UC), which share similar clinical symptoms but differ in the anatomical distribution of the inflammatory lesions. The etiology of IBDs is undetermined. Several hypotheses suggest that Crohn’s Disease and Ulcerative Colitis result from an abnormal immune response against endogenous flora and luminal antigens in genetically susceptible individuals. While there is no cure for IBDs, most common treatments (medication and surgery) aim to reduce inflammation and help patients to achieve remission. There is growing evidence and focus on the prophylactic and therapeutic potential of probiotics in IBDs. Probiotics are live microorganisms that regulate the mucosal immune system, the gut microbiota and the production of active metabolites such as Short-Chain Fatty Acids (SCFAs). This review will focus on the role of intestinal dysbiosis in the immunopathogenesis of IBDs and understanding the health-promoting effects of probiotics and their metabolites.


2011 ◽  
Vol 140 (5) ◽  
pp. S-787
Author(s):  
Marta Iglesias-Rey ◽  
Manuel Barreiro-de Acosta ◽  
Isabel Vazquez ◽  
Maria Piñeiro ◽  
Adolfo Figueiras ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Ilse Molendijk ◽  
Marjolijn Duijvestein ◽  
Andrea E. van der Meulen-de Jong ◽  
Welmoed K. van Deen ◽  
Marloes Swets ◽  
...  

The ability of mesenchymal stromal cells (MSCs) to suppress immune responses combined with their potential to actively participate in tissue repair provides a strong rationale for the use of MSCs as a new treatment option in diseases characterized by inflammation and severe tissue damage, such as Crohn’s disease (CD) and perianal fistulas. Multiple studies have shown that MSCs suppress a range of immune cells, such as dendritic cells (DC), naïve and effector T cells, and natural killer (NK) cells. Recently published papers attribute the immunosuppressive capacity of MSCs to soluble factors produced by MSCs, such as prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), and indoleamine 2,3-dioxygenase (IDO). Promising results are obtained from phase I and II clinical trials with autologous and allogeneic MSCs as treatment for refractory CD and perianal fistulas; however the question remains: what are the molecular mechanisms underlying the immunomodulating properties of MSCs? This paper highlights the present knowledge on the immunosuppressive effects of MSCs and its complexity in relation to CD and perianal fistulas.


2015 ◽  
Vol 149 (4) ◽  
pp. 918-927.e6 ◽  
Author(s):  
Ilse Molendijk ◽  
Bert A. Bonsing ◽  
Helene Roelofs ◽  
Koen C.M.J. Peeters ◽  
Martin N.J.M. Wasser ◽  
...  

2013 ◽  
Vol 45 ◽  
pp. S71
Author(s):  
R. Ciccocioppo ◽  
G.C. Cangemi ◽  
E. Betti ◽  
A. Gallia ◽  
V. Imbesi ◽  
...  

2018 ◽  
Vol 50 (11) ◽  
pp. 1251-1255 ◽  
Author(s):  
Céline Gregoire ◽  
Alexandra Briquet ◽  
Caroline Pirenne ◽  
Chantal Lechanteur ◽  
Edouard Louis ◽  
...  

2012 ◽  
Vol 142 (5) ◽  
pp. S-779
Author(s):  
Renate Schmelz ◽  
Stefan Brueckner ◽  
Jana Babatz ◽  
Katja Richter ◽  
Nadine Muench ◽  
...  

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S163-S163
Author(s):  
S Coll ◽  
C Bauset ◽  
J Cosín-Roger ◽  
D Ortiz-Masià ◽  
L Gisbert-Ferrándiz ◽  
...  

Abstract Background Crohn’s Disease (CD) patients often develop stenotic complications as immunomodulatory treatments do not prevent the fibrogenic response in the affected tissues, where a dysregulated activation of stromal cells provokes an excessive deposition of extracellular matrix (ECM). Recent evidences support the notion that local cells can sense the consequent alterations in tissue structure and rigidity through receptors that respond to some ECM components, and this may perpetuate the fibrogenic process even in the absence of inflammation. We aim to analyse the relevance of these signalling pathways in the fibrotic process associated to CD. Methods We obtained fibrotic ileal tissues from CD patients and healthy ileal samples from colon carcinoma patients (control), and analysed the expression (RT-PCR, IHQ) of collagen receptors (integrins, discoidin domain receptors/DDR) and of markers for some stromal cells (fibroblasts, endothelial cells). The relationship between these sets of data was analysed by Pearson’s correlation and the results organized as a correlation matrix. The expression of collagen receptors was also analysed in endothelial cells (HUVEC) treated with TGFβ 2 (1ng/ml, 48h). Results Ileal samples from CD patients present a differential gene expression of collagen receptors (Fig 1), with increased levels of ITGA10, ITGA11 and DDR2, and reduced expression of DDR1. In CD tissues, the expression of ITGA11 and DDR1 showed a significant correlation, positive and negative respectively, with that of endothelial markers (Fig 2). These correlations do not occur in control tissues. Integrin-α11 was detected in endothelial cells of submucosal vessels (IHQ). In HUVEC, TGFβ 2 increased the expression of ITGA11 (8.1±0.7 fold induction, p<0.01) and reduced that of DDR1 (0.74±0.06 fold induction, p<0.01), without affecting that of the other collagen receptors. Conclusion Intestinal tissues from CD patients affected by fibrosis present an altered pattern of expression of collagen receptors, which suggests a regulatory role of the ECM in the fibrotic response, while the correlation analysis and the changes induced by the fibrotic cytokine TGFβ in endothelial cells insinuates a particular relevance of these stromal cells in this process.


Sign in / Sign up

Export Citation Format

Share Document